Neovascular Age-related Macular Degeneration (nAMD) Clinical Trial
Official title:
Safety and Tolerability of Single Ascending Doses and Multiple Repeat Doses of OCU-10-C-110 for Injection in Study Participants With Neovascular Age-related Macular Degeneration (nAMD)
Multi-center, open-label, two-part safety assessment following administration of single ascending doses and repeat administration of the HTD of OCU-10-C-110 for Injection in the study eye of participants with nAMD
In Part A, subjects will receive a single intravitreal dose in a single eye of the drug product. Dose will be escalated in 3 successive cohorts, pending safety. In Part B, subjects will receive 3 treatments in a single eye of drug product at 4 week intervals of the maximally tolerated dose, with an additional 4 weeks of observation for safety. . ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04543331 -
Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema
|
||
| Completed |
NCT05282004 -
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit
|
Phase 3 | |
| Active, not recruiting |
NCT04764656 -
Observational Study to Evaluate Fluid Resolution and Effectiveness of Brolucizumab for nAMD in Portugal
|
||
| Completed |
NCT05269966 -
Study to Evaluate the Safety and Effectiveness of Intravitreal Injections (IVI) of Brolucizumab in Patients With Neovascular Age-related Macular Degeneration (nAMD)
|
Phase 4 | |
| Completed |
NCT05161806 -
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe
|
Phase 3 | |
| Recruiting |
NCT04657289 -
A Study of the Efficacy, Safety, and Pharmacokinetics of A 36-Week Refill Regimen for the Port Delivery System With Ranibizumab in Patients With Neovascular Age-Related Macular Degeneration (Velodrome)
|
Phase 3 | |
| Recruiting |
NCT06116890 -
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration
|
Phase 2 | |
| Recruiting |
NCT06075147 -
The SPECTRUM Study: An Observational Study to Learn More About How Well Aflibercept 8 mg Works in Treating Visual Impairment Due to Neovascular Age-related Macular Degeneration or Diabetic Macula Edema
|
||
| Terminated |
NCT04746963 -
Safety and Bioactivity of AXT107 in Subjects With Neovascular Age-Related Macular Degeneration
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05769153 -
Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)
|
Phase 1/Phase 2 | |
| Enrolling by invitation |
NCT05210803 -
Long-Term Follow-Up Study of RGX-314 Administered in the Suprachoroidal Space for Participants With nAMD
|
||
| Recruiting |
NCT04514653 -
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Neovascular Age-Related Macular Degeneration (nAMD)
|
Phase 2 | |
| Not yet recruiting |
NCT06398080 -
An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting
|
||
| Active, not recruiting |
NCT05989126 -
Study to Evaluate an 8 mg Aflibercept (EYLEA®) Prefilled Syringe (PFS)
|
Phase 3 |